【摘要】：目的:分析卵巢子宮內(nèi)膜異位癥(EMs)惡變的臨床病理特征。方法:回顧分析2011年12月至2015年12月于鄭州大學(xué)人民醫(yī)院婦科行手術(shù)治療且術(shù)后病理確診的卵巢癌患者281例,其中符合內(nèi)異癥惡變診斷標(biāo)準(zhǔn)者24例(內(nèi)異癥惡變組),非內(nèi)異癥惡變者257例(非內(nèi)異癥惡變組)。分析兩組患者的臨床組織病理學(xué)類型及FIGO分期。結(jié)果:與非內(nèi)異癥惡變組相比,內(nèi)異癥惡變組患者的平均年齡早、絕經(jīng)前診斷比例較大,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。內(nèi)異癥惡變組術(shù)前CA125值(110.27±112.62)U/ml,腹水量較少、病理類型多為透明細(xì)胞癌(45.83%)、FIGO分期早期(87.50%);非內(nèi)異癥惡變組術(shù)前CA125值(1242.75±2104.28)U/ml、腹水量較多,病理類型多為漿液性腺癌(72.37%),FIGO分期晚期(74.71%);兩組比較,差異均有統(tǒng)計(jì)學(xué)意義(P均0.05)。兩組患者在癌灶單雙側(cè)及淋巴結(jié)轉(zhuǎn)移情況比較,差異均無統(tǒng)計(jì)學(xué)意義(P均0.05)。結(jié)論:卵巢內(nèi)異癥惡變患者發(fā)病年齡小、腹水量少、術(shù)前CA125較低、FIGO期別早,組織病理以透明細(xì)胞癌及子宮內(nèi)膜樣腺癌為主。
[Abstract]:Objective: to analyze the clinicopathological features of (EMs) malignancy in ovarian endometriosis. Methods: from December 2011 to December 2015, 281 patients with ovarian cancer treated by gynecologic surgery and confirmed by pathology in Renmin Hospital of Zhengzhou University were retrospectively analyzed. Among them, 24 cases were in accordance with the diagnostic criteria of malignant change of endometriosis (malignant change group) and 257 cases were non-malignant change group (non-malignant group). The clinicopathological types and FIGO staging of the two groups were analyzed. Results: compared with non-endometriosis group, the average age and premenopausal diagnosis of the patients were earlier and the difference was statistically significant (P0.05). The preoperative CA125 value was (110.27 鹵112.62) U / ml, the quantity of ascites was less and the pathological type was clear cell carcinoma (45.83%) early stage of Figo stage (87.50%), the preoperative CA125 value was (1242.75 鹵2104.28) U / ml, and the pathological type was serous adenocarcinoma (72.37%) late stage of Figo stage (74.71%). The difference was statistically significant (P 0.05). There was no significant difference between the two groups (P 0.05). Conclusion: the patients with malignant change of ovarian endometriosis are young in age, less in ascites, lower in CA125 before operation and earlier in Figo stage. The histopathology is mainly clear cell carcinoma and endometrial adenocarcinoma.
【作者單位】： 鄭州大學(xué)人民醫(yī)院;
【基金】：河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃(No:201301007)
【分類號】：R737.31
，

本文編號：2203226